Women In Longevity – Dr. Joan Mannick On Clinical Development For Aging
In 2014 ResTORbio spun off out of Novartis and went public to try a longevity drug as a vaccine-potentiating agent in the elderly. The company was led by Dr. Joan Mannick, a physician with deep interest in aging. The trial failed in Phase III providing valuable experience, and her work continues.
Insilico Medicine Cambrian Biopharma Unity Biotechnology Joan Mannick Aging Research Longevity Therapeutics
Source: forbes.com